Item 2.02 - Results of Operations and Financial Condition: The filing reports AbbVie's financial results and operational performance as of July 31, 2026 Item 9.01 - Financial Statements and Exhibits: The filing includes financial statements and exhibits related to the reported results Filing Date: Current report filed on July 31, 2026, covering the earliest event reported on the same date Company…

Our analysis rates this filing NEUTRAL. AbbVie presents a balanced, moderately concerning but fundamentally stable picture. The company is executing well operationally with 10.2% overall revenue growth and strong momentum in core immunology and neuroscience portfolios. However, near-term EPS is…

Concern level: ELEVATED (4.2/10). Key factors: Guidance range narrowed and midpoint reduced by $0.04, reflecting $0.58/share IPR&D and milestone charges from recent acquisitions; Near-term EPS dilution of $0.14/share expected from Apogee Therapeutics acquisition closing Q3 2026; Oncology portfolio revenue declined 1.5% reported (2.4% operational basis), with Venclexta and Imbruvica facing…

Notable risk changes: Guidance range narrowed and lowered: $13.91-$14.11 to $13.87-$14.07 (midpoint down $0.04), reflecting $0.58 per share IPR&D/milestones charges and $0.14 per share Apogee dilution; Strong immunology portfolio momentum: Skyrizi revenues surged to $5.505B (+15.1% reported), Rinvoq to $2.525B, offsetting Humira decline to $756M - demonstrates successful transition strategy execution; Neuroscience…